slidedeck.co

Moderna investor presentation, Oncology Event, ESMO 2026

Cover slide of the Moderna 2026 investor presentation
Cover of Moderna's 2026 investor presentation.

The deck opens with a cover for Moderna's oncology event dated October 2026, followed by standard forward-looking statements and an agenda listing speakers and key opinion leader perspectives. The core section introduces intismeran, an individualized mRNA neoantigen therapy, through a short run of explanatory diagrams: how the immune system detects cancer, how cancers escape surveillance, how checkpoint inhibitors act on T cells, and how intismeran improves neoantigen presentation. Clinical evidence follows, with 5-year KEYNOTE-942 recurrence-free survival curves and T cell clonality charts, then a Phase 3 INTerpath-001 melanoma section presented by Georgina Long. Later slides cover unmet need in other adjuvant cancer settings, Phase 2 melanoma data by tumour mutational burden, and a Phase 1 pancreatic cancer study. The deck closes with a partnership slide noting the program is partnered with Merck, a conclusion by David Berman, perspectives from two external physicians, and a Q&A slide. Many slides in the middle are image-only, and the clinical charts are dense with small labels. Each section is introduced with a clear headline, and the explanatory diagrams carry the argument with little text.

Slides worth studying

  • Slide 5: A simple two-panel diagram with a headline stating the idea shows the immune cycle with minimal text, a clear model for explaining mechanism.
  • Slide 9: Numbered steps beside an anatomical illustration with callouts guide the eye through how the therapy works in sequence.
  • Slide 46: A grid of cancer types with recurrence rates and footnoted sources makes a comparison across indications easy to scan.

Details

  • Company: Moderna
  • Year: 2026
  • Type: Investor presentation
  • Industry: Biotechnology
  • Pages: 52

The hosted copy of this deck is being prepared. Newsletter readers will find the download here.

Review score: 7 out of 10, Effective

Presentation quality, judged with the SlideDeck Co review heuristic. Ask, evidence and idea merit are not rated here.

The company-authored slides have strong action headlines in a consistent red and navy system, and the mechanism diagrams on slides 5 to 9 carry a clear explanation with little text. Slide 46 is a good example: big red percentages, icons and one takeaway. The route from mechanism to evidence to Phase 3 to other cancers to conclusion is easy to follow, and the speaker and KOL slides give clear changes of voice. The weaknesses are consequential: slides 19 to 45 are a pasted external ESMO presentation with a different template, 8 to 10 pt footnotes and tiny chart labels, and slides 10 to 15 and 21 to 22 use small charts that the audience cannot read from the room. Slide 2 is a full wall of legal text, and the placeholder pixelated logo blocks recur in the bottom right corner on most slides.

Worth keeping: Keep the action headlines, the lightly annotated mechanism diagrams on slides 5 to 9, and the icon and big-number layout of slide 46.

Most useful repair: Fix the pixelated logo block on slides 6 to 18 and 46 to 52, and enlarge the KEYNOTE-942 charts on slides 10 to 12 so their labels and hazard ratios are legible.

What would change the score: I would cut the 27-slide ESMO insert (19 to 45) to a handful of restyled key results, such as the RFS curve, the subgroup forest plot and the adverse event summary, with the rest moved to an appendix.

Confidence medium. 52 of 52 pages inspected on contact sheets, 4 at readable size. Reviewed 2026-11-10. Model-assisted review (claude-sonnet-5-5).

Full text of the slides (52 slides)

Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.

Slide 1

Moderna

Oncology Event

October 24, 2026

Visuals: Right-side photo collage on a 44.5% wide by full-height area, made of rounded-corner tiles on a honeycomb-like grid separated by #25638A gutters. Top-left tile: solid light sky-blue #7FCBEA block. Top-right tile: microscopy image of blue-white cell clusters with magenta-red nuclei, cropped at the top and right edges. Centre tile: photograph of a Black male scientist in a white lab coat with a Moderna badge, blue surgical mask, safety glasses and blue nitrile gloves, holding a pipette over a red-liquid sample; bright overhead fluorescent lighting, cool blue-white palette, shallow focus, three-quarter view. Right-middle tile: solid light sky-blue #7FCBEA block. Bottom-centre tile: small pink and purple histology micrograph of tissue cells. Bottom-right tile: close-up of a gloved hand dispensing red liquid from a barcoded tube onto a white textured surface, cool white and red palette, cropped at the bottom and right edges. Logo: white lowercase 'moderna' wordmark with a small registered mark and a row of white dashes beneath it.

Slide 2

Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: intismeran's potential in cancer care and to set a new benchmark for adjuvant melanoma treatment; intismeran's clinical development program, including ongoing clinical trials and the timing of potential readouts; the potential of intismeran in other tumor types and across settings; Phase 1 pancreatic cancer data; efficacy and safety; the trend in overall survival data; the ability for intismeran to be supplied at scale; and the potential long-term benefit of intismeran. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this presentation.

2

© 2026 Moderna, Inc. All rights reserved.

moderna

Visuals: none apart from the moderna logo: a red lowercase wordmark 'moderna' with a row of short cyan dashes beneath it, placed bottom-right as a flat logo image measuring 245 by 56 pixels, not cropped, not boxed, no overlay.

Slide 3

Agenda / Intismeran: Advancing individualized / cancer immunotherapy / David Berman, MD, PhD / Chief Development Officer, Moderna / INTerpath-001: Phase 3 Study of the mRNA-Based / Individualized Neoantigen Therapy (INT) Intismeran / Autogene plus Pembrolizumab vs Pembrolizumab Alone for / Adjuvant Treatment of Resected Stage IIB-IV Melanoma / Georgina Long, AO BSc PhD MBBS FRACP FAHMS / AAHMS FAA FASCO / Medical Director of Melanoma Institute Australia / Conclusion / David Berman, MD, PhD / Chief Development Officer, Moderna / Key opinion leader perspectives / Paolo Ascierto, MD / Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics, / National Cancer Institute IRCCS, Fondazione G. Pascale Naples / Antoni Ribas, MD, PhD / Professor of Medicine, Surgery, and Molecular and Medical Pharmacology, UCLA / Q&A / 3 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Decorative elements only: five light blue (#DFEAF5) rounded panels acting as row backgrounds, four thin horizontal rule lines separating the panels (two dark navy lines at about y 25.8% and 41.9%, about 0.15% thick, and two red lines at about y 54.8% and 79.1%, about 0.2% thick, spanning about x 5.4% to 97.6%), a dark blue vertical bar on the left edge, and the Moderna logo at bottom right: the wordmark 'moderna' in red (about #E31837) lowercase letters with a row of short cyan (about #00B5E2) dashes beneath it. Image is 123 by 28 pixels, not cropped, unboxed. No photographs, charts or diagrams.

Slide 4

Intismeran:

Advancing individualized

cancer immunotherapy

David Berman, MD, PhD

Chief Development Officer, Moderna

© 2026 Moderna, Inc. All rights reserved.

moderna

Visuals: A small moderna wordmark logo in the bottom-right corner, lowercase pinkish-red letters on white with a thin cyan dashed underline beneath the letters; it is a raster image of 62 by 14 pixels. No photographs, charts or other graphics.

Slide 5

Immune surveillance controls emerging cancer cells

Immune system detects cancer antigens

(neoantigens)

Neoantigens drain to lymph node and are presented

by antigen presenting cells (APC) to T cells

Activated T cells eliminate cancer

Neoantigen-reactive T cells are activated and target the cancer

Gavin P., et al. 2004. The Three Es of Cancer Immunoediting. Annual Review of Immunology 22:329-360.

5

© 2026 Moderna, Inc. All rights reserved.

Visuals: Left: a scientific illustration on a white boxed panel showing pink tumour cells at the left with scattered grey dots and small bright green dots drifting rightwards in a stream into a large purple lymph node containing clusters of pale blue T cells and purple dendritic cells; from the far side of the node, a fan of about five pale blue T cells with small blue arrows exits to the right. Composition is horizontal, full illustration visible, boxed on a faint off-white panel, no cropping, soft flat vector lighting, dominant colours purple, pale blue, pink and grey with green accents. Centre: a solid blue arrow pointing right, no label. Right: a boxed illustration of two pale blue T cells at upper-left and lower-left, each with a dark navy Y-shaped receptor binding a small pink capsule with a green dot; to the right a large dense cluster of red-pink cancer cells with splattered fragments dissolving across the frame, flat vector style, white background, no cropping. No charts, tables, or graphs.

Slide 6

Cancers can escape immune surveillance when…

APCs do not activate T cells

Insufficient neoantigen processing,

presentation, or T cell activation

T cells become exhausted

e.g. PD1/PDL1

6

© 2026 Moderna, Inc. All rights reserved.

Visuals: 1) Left illustration (x 5.8%, y 31.7%, 41.7% by 45.9%, boxed on a near-white field): a cluster of pink-red tumour cells at far left shedding small dark grey dots and a few green dots that travel rightward in a trail to a large purple-outlined lymph node or organ on the right. Inside the node are purple dendritic-like cells (spiky purple shapes) and several clusters of light blue circles with blue outlines (lymphocytes), with a purple tubular vessel entering from the left and small purple protrusions on the right. The image is flat vector-style, with light lavender and blue dominant colours, pink-red tumour cells, and a faint off-white background with no overlay. 2) Right illustration (x 61.7%, y 34.8%, 32.6% by 38.6%, no visible box): a dense mass of pink tumour cells with pale pink nuclei and red spiky surface markers, with two pale light-blue circles with blue outlines (T cells) at upper left and lower left, each bound to the tumour by small red-and-blue Y-shaped receptor markers. Several smaller pink tumour clusters drift off to the right, connected by thin pink arrows pointing right to three detached clusters at upper right, middle right and lower right. Dominant colours are salmon pink, red and light blue. 3) Blue right-pointing arrow (about x 51%, y 56.5%, 6.3% wide, 2.5% high): solid #29ABE2 shaft and filled triangular head. 4) Small pixelated strip (x 86.6%, y 92.2%, 12.2% by 4.9%): a 16 by 4 pixel mosaic of pink, mauve and pale grey-blue blocks, with no legible content.

Slide 7

Checkpoints act on T cells, but are limited by available neoantigens

Anti-CTLA-4

Lowers threshold

for T cell activation

Anti-PD-1

Reverse T cell exhaustion

7

© 2026 Moderna, Inc. All rights reserved.

Visuals: Left illustration (photo-like raster, boxed, not cropped): a cluster of pink-red tumour cells with dark grey and bright green dots drifting along a lilac vessel toward a large lilac lymph node. Inside the node are clusters of light blue T cells and purple spiky dendritic cells, and blue cells exit the node on the right via thin blue arrows to three blue cells with arrowheads. A purple arrow points from the callout to a T cell cluster. Callout box (Anti-CTLA-4): lilac rounded box with a purple antibody icon, purple title Anti-CTLA-4 and dark text Lowers threshold for T cell activation. Blue horizontal arrow (solid, #29ABE2, arrowhead on right) between the panels. Right illustration (boxed, not cropped): a dense mass of pink tumour cells with red surface markers and fragmented pink debris at the right edge; two light blue T cells with blue rings sit at upper-left and lower-left, each bound to an orange Y-shaped antibody. Orange arrow points from callout to lower T cell. Callout box (Anti-PD-1): pale peach rounded box with an orange antibody icon, orange title Anti-PD-1 and dark text Reverse T cell exhaustion. Illustrations have a near-white background with soft shading, no overlay.

Slide 8

Intismeran optimizes neoantigen presentation / Intismeran / Selects best neoantigens / for maximal T cell education / Anti-CTLA-4 / Lowers threshold / for T cell activation / Anti-PD-1 / Reverse T cell exhaustion / 8 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Scientific illustration, left to right: (1) A purple-outlined silhouette of a human upper body and arm, with a syringe entering the upper arm; a light-blue magnified circular inset (with a cone-shaped light-blue connector from the syringe) shows three blue DNA/mRNA strand bubbles inside cells. (2) A cluster of red-outlined, pinkish round tumour cells with dark dots scattered beside it; a dotted trail of dark grey, green and blue-grey dots runs from it toward the central structure. (3) A large purple-outlined lymph-node-like organ with a dense cluster of light-blue T cells, purple and grey virus-like spiky particles, and small coloured dots (orange, yellow, green, red, blue) inside; a small cluster of light-blue cells sits on its left and bottom. Two blue curved arrows lead into it from the left and top. Light-blue T cells with arrows radiate out to the right from its right side (about eight cells with blue arrowheads). (4) A solid blue arrow pointing right separates the centre from the right panel. (5) A red-and-pink cancer cell mass with many spiky red receptor marks and pale pink dying/fragmented cells on its right side; two light-blue T cells with orange Y-shaped antibody shapes attach to its upper-left and lower-left edges, with a small orange arrow pointing up at the lower one. Callout boxes: a light-blue rounded box with blue outline, containing a DNA-bubble icon, then bold blue 'Intismeran' and body text; a lavender/purple rounded box with purple outline, containing a purple Y-shaped antibody icon; an orange-outlined pale-peach rounded box with an orange Y-shaped antibody icon. Lighting is flat; the illustration sits on an almost-white background with faint grey tint panels behind the image band. No photograph is present.

Slide 9

How intismeran activates tumor-specific T cells / 1 / Algorithm selects most / promising neoantigens / 2 / mRNA-LNP delivers neoantigens / to APCs in lymph node / mRNA-LNP / High neoantigen expression / Neoantigen-derived peptides produced / and presented in antigen presenting cell / Optimal environment / Activation in lymph node away from / immunosuppressive tumor / microenvironment / Polyfunctional T cells / Cytokines support CD4+ and CD8+ / T-cell proliferation, differentiation, / and acquisition of effector functions / Tumor / Lymph node / 9 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Illustration (single placed image, 1904 by 826 pixels, box x 4.4% y 28.2% w 69.9% h 53.9%, boxed on a near-white background, not full-bleed): left, a cluster of pink-coral tumor cells with red spiky edges and small coloured dots (teal, orange, blue, purple, yellow) in each cell, with a bracket linking to four stacked coloured dots (teal, orange, blue, purple) and a small blue gradient arrow pointing right. Centre, a red outline sketch of a standing human figure with a small dark red spot on the shoulder, a blue syringe injecting at the right shoulder with a thin purple line running from the injection site up to a mRNA-LNP particle. Right, a large pale lilac lymph node outline with purple vessels at its corners, containing two small blue-circled mRNA-LNP particles with wavy symbols entering from the upper left, purple-pink dendritic antigen presenting cells, small red dots, a grey central cell with multicoloured antigen bars radiating outward, and four or five light blue circular T cells with cyan outlines. Blue callout lines (about 0.5% of slide height thick) connect from the right-hand text blocks to a lymph-node point and to the cells. Lighting flat, no shadows; dominant colours red, coral pink, light blue, lilac and grey. Pink mosaic image at bottom right is an 8 by 2 pixel pattern of pale pinks, full box x 86.6% y 92.2% w 12.2% h 4.9%.

Slide 10

5-year KEYNOTE-942 data, oral abstract presentation, ASCO 2026 / RFS benefit maintained through 5-year follow up / Primary Analysis: Nov 14, 2022¹ / + Censored / Recurrence-Free Survival, % / 100 90 80 70 60 50 40 30 20 10 0 / 0 6 12 18 24 30 36 42 48 / Time From First Dose of Pembrolizumab, Months / Intismeran plus pembrolizumab / pembrolizumab / 107 88 82 49 24 8 3 0 0 / Pembrolizumab / 50 41 37 28 11 1 1 0 0 / Events, % (n/N) / Hazard Ratio (95% CI) / Intismeran plus pembrolizumab / 22.4 (24/107) / 0.561 (0.309–1.017) / P = 0.0266ᵇ / Pembrolizumab / 40.0 (20/50) / 5-Year Analysis: Dec 15, 2025 / + Censored / Recurrence-Free Survival, % / 100 90 80 70 60 50 40 30 20 10 0 / 0 6 12 18 24 30 36 42 48 54 60 66 / Time From First Dose of Pembrolizumab, Months / 107 89 84 78 74 70 57 55 39 20 3 0 / 50 41 37 29 27 22 19 17 12 7 3 0 / Events, % (n/N) / Hazard Ratio (95% CI) / Intismeran plus pembrolizumab / 26.2 (28/107) / 0.510 (0.294–0.887) / Pembrolizumab / 46.0 (23/50) / ᵃFormal hypothesis testing of RFS (overall one-sided α=0.10) was performed at primary analysis (Nov 2022 data cut). / 1. Weber JS, et al. Lancet. 2024;403(10427):632-644. / 10 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Two Kaplan-Meier survival charts, side by side, each with a grey label box above it. Left chart: titled 'Primary Analysis: Nov 14, 2022' with superscript 1; x-axis 'Time From First Dose of Pembrolizumab, Months', ticks 0 to 48 every 6 months; y-axis 'Recurrence-Free Survival, %', 0 to 100 every 10. Two series: red line 'Intismeran plus pembrolizumab' and blue line 'Pembrolizumab'; both step down with tick marks for censored patients; legend '+ Censored' at top right. Printed values are only the at-risk counts: red 107, 88, 82, 49, 24, 8, 3, 0, 0 and blue 50, 41, 37, 28, 11, 1, 1, 0, 0 at 0 to 48 months. About 58% red and about 55% blue at the end of follow-up near 48 months (no printed value). Right chart: titled '5-Year Analysis: Dec 15, 2025'; x-axis 0 to 66 every 6 months; same y-axis and series colours; red ends about 69% at about 60 months and blue ends about 49% at about 60 months (no printed value). At-risk counts right: red 107, 89, 84, 78, 74, 70, 57, 55, 39, 20, 3, 0; blue 50, 41, 37, 29, 27, 22, 19, 17, 12, 7, 3, 0. Below each chart is a table with a dark slate-blue header row (#264E6E) and a light grey body (#F2F2F2). Left table columns: blank, 'Events, % (n/N)', 'Hazard Ratio (95% CI)'. Rows: 'Intismeran plus pembrolizumab' red text 22.4 (24/107) and '0.561 (0.309–1.017) / P = 0.0266' with superscript b; 'Pembrolizumab' blue text 40.0 (20/50). Right table: 'Intismeran plus pembrolizumab' red 26.2 (28/107) and 0.510 (0.294–0.887); 'Pembrolizumab' blue 46.0 (23/50). A navy (#0B2A6B) rectangle outline boxes the hazard ratio column in each table. Pink mosaic image bottom right: 8 by 2 tiles in pale pink shades (#F7D3DC to #E8A9B9), not cropped.

Slide 11

5-year KEYNOTE-942 data, oral abstract presentation, ASCO 2026 / Intismeran plus pembrolizumab induces more novel T cell clones / 11 / © 2026 Moderna, Inc. All rights reserved. / Summed Frequency of Novel Expanded Clonotypes, Median (95% CI) / 0.03 / 0.02 / 0.01 / 0.00 / Intismeran plus pembrolizumab / Pembrolizumab / Baseline / Pre-intismeran/ post-pembrolizumab Cycle 2/Day 1 / Post-intismeran/ post-pembrolizumab Cycle 5/Day 1 / Long-term follow-up / Intismeran plus pembrolizumab n=78 n=69 n=73 n=56 / Pembrolizumab n=38 n=32 n=35 n=23

Visuals: Line chart with error bars, placed as a bitmap (623 by 344 px) in a plain rectangular box with no border. Title: none printed above the chart. Y-axis label reads 'Summed Frequency of Novel Expanded Clonotypes, Median (95% CI)', rotated vertical, range 0.00 to about 0.035 with labelled ticks at 0.00, 0.01, 0.02, 0.03. X-axis categories: Baseline; Pre-intismeran/post-pembrolizumab Cycle 2/Day 1; Post-intismeran/post-pembrolizumab Cycle 5/Day 1; Long-term follow-up. Series 1, Intismeran plus pembrolizumab (red #E31837 line with open red circle markers, thick line): Baseline about 0.000; Pre-intismeran about 0.016 with error bar about 0.011 to 0.021; Post-intismeran about 0.027 with error bar about 0.019 to 0.036; Long-term about 0.030 with error bar about 0.001 to 0.035. Series 2, Pembrolizumab (light blue #1FA2DC line with open blue circle markers): Baseline about 0.000; Pre-intismeran about 0.018 with error bar about 0.007 to 0.024; Post-intismeran about 0.014 with error bar about 0.003 to 0.019; Long-term about 0.016 with error bar about 0.000 to 0.022. Legend: boxed in the upper-left plot area with black 1 px border, white fill, red marker entry 'Intismeran plus pembrolizumab' and blue marker entry 'Pembrolizumab'. A black dashed horizontal reference line at 0.00 across the plot. Plot frame is a black rectangular border around the plot area with light grey horizontal gridlines. Below the axis, a table in the image: row 'Intismeran plus pembrolizumab' in red values n=78 (Baseline), n=69 (Pre-intismeran), n=73 (Post-intismeran), n=56 (Long-term follow-up); row 'Pembrolizumab' in blue values n=38, n=32, n=35, n=23 in the same column order. Highlighted points: none. Separately, a decorative tile strip at bottom right: 8 by 2 pixel mosaic of pink squares in graded tints from pale pink to light mauve, no photograph.

Slide 12

5-year KEYNOTE-942 data, oral abstract presentation, ASCO 2026

Patients without recurrence on intismeran plus pembrolizumab showed

greater expansion of novel T cell clones

Intismeran Plus Pembrolizumab

Unique Novel / Expanded Clonotypes, / Median (95% CI)

Intismeran plus pembrolizumab / No recurrence / Recurrence

60 / 40 / 20 / 0

Baseline / Pre-intismeran/ / post-pembrolizumab / Cycle 2/Day 1 / Post-intismeran/ / post-pembrolizumab / Cycle 5/Day 1 / Long-term / follow-up

No recurrence n=57 / Recurrence n=21 / n=49 / n=20 / n=54 / n=19 / n=43 / n=13

Pembrolizumab

Unique Novel / Expanded Clonotypes, / Median (95% CI)

Pembrolizumab / No recurrence / Recurrence

60 / 40 / 20 / 0

Baseline / Post-pembrolizumab / Cycle 2/Day 1 / Post-pembrolizumab / Cycle 5/Day 1 / Long-term / follow-up

No recurrence n=21 / Recurrence n=17 / n=17 / n=15 / n=19 / n=16 / n=14 / n=9

Data are shown as median and bootstrapped 95% CI. Whole blood TCR RNA sequencing at baseline, pre-intismeran/post-pembrolizumab (Cycle2/Day1), post-intismeran/post-pembrolizumab (Cycle5/Day1),

and 30 days after the last pembrolizumab dose. Long-term follow-up data were collected at >170 days after last intismeran dose.

12

© 2026 Moderna, Inc. All rights reserved.

Visuals: Two line charts with error bars, side by side. Left chart titled 'Intismeran Plus Pembrolizumab': y-axis 'Unique Novel Expanded Clonotypes, Median (95% CI)' ranging 0 to about 75 with ticks at 0, 20, 40, 60; x-axis categories Baseline, Pre-intismeran/post-pembrolizumab Cycle 2/Day 1, Post-intismeran/post-pembrolizumab Cycle 5/Day 1, Long-term follow-up. Series 'No recurrence' (red #E31837 line with circle markers): about 0 at baseline, about 15 at Cycle 2/Day 1 (error bar about 10 to 20), about 28 at Cycle 5/Day 1 (about 25 to 31), about 42 at long-term follow-up (about 35 to 48). Series 'Recurrence' (dark maroon #8C2F5B line with circle markers): about 0 at baseline, about 15 at Cycle 2/Day 1 (error bar about 3 to 20), about 15 at Cycle 5/Day 1 (about 0 to 20), about 20 at long-term follow-up (about 16 to 24). Dashed black horizontal reference line at 0. Legend box at top-left inside plot. Right chart titled 'Pembrolizumab': same y-axis (0 to about 75). Series 'No recurrence' (light blue #29ABE2 with open circle markers): 0 at baseline, about 29 at Cycle 2/Day 1 (about 23 to 42), about 29 at Cycle 5/Day 1 (about 21 to 44), about 24 at long-term follow-up (about 20 to 27). Series 'Recurrence' (dark blue #1F5C99 with open circle markers): 0 at baseline, about 19 at Cycle 2/Day 1 (about 12 to 23), about 11 at Cycle 5/Day 1 (about 8 to 14), about 21 at long-term follow-up (about 8 to 35). Dashed black reference line at 0. Legend box at top-left. Below the left chart a sample size table: rows 'No recurrence' n=57, n=49, n=54, n=43 in red; 'Recurrence' n=21, n=20, n=19, n=13 in maroon. Below the right chart: 'No recurrence' n=21, n=17, n=19, n=14 in light blue; 'Recurrence' n=17, n=15, n=16, n=9 in dark blue. Pink mosaic tile graphic at bottom-right, about 12.2% by 4.9% of the slide, pale pink squares, no text.

Slide 13

5-year KEYNOTE-942 data, oral abstract presentation, ASCO 2026 / Intismeran induces neoantigen-specific T cells / Neoantigens recognized by patient’s T cells / CD8+ and CD4+ / CD4+ only / CD8+ only / 1 / 2 / 3 / 4 / 5 / 6 / 7 / Patient / 0 / 5 / 10 / 15 / 20 / Number of immunogenic neoantigens / * Hotspot mutation / On average 1 of 3 selected / neoantigens induce T cell / response / Induces both CD4 and CD8 / neoantigen reactive T cells / 13 / © 2026 Moderna, Inc. All rights reserved.

Visuals: A horizontal stacked bar chart, untitled on its own axes, with the heading 'Neoantigens recognized by patient’s T cells'. Y axis: 'Patient' with categories 1 to 7 from top to bottom, no numeric scale. X axis: 'Number of immunogenic neoantigens', linear from 0 to 20, ticks at 0, 5, 10, 15, 20. Three stacked series per bar, in left-to-right order: light-blue CD8+ only, navy CD4+ only, red CD8+ and CD4+. Legend at upper right of plot, top to bottom: red 'CD8+ and CD4+', navy 'CD4+ only', light blue 'CD8+ only'. Estimated values (none printed, so all about): Patient 1: CD8+ only about 1, total about 1. Patient 2: CD8+ only about 3, red about 1, total about 4. Patient 3: CD8+ only about 4 (with a white asterisk), CD4+ only about 5 (4 to 9), red about 3 (9 to 12), total about 12. Patient 4: CD8+ only about 3, CD4+ only about 8 (3 to 11), red about 7 (11 to 18), total about 18, with a white asterisk on the red segment. Patient 5: CD8+ only about 5, CD4+ only about 3 (5 to 8), red about 3 (8 to 11), total about 11. Patient 6: CD4+ only about 7 (0 to 7), red about 4 (7 to 11), total about 11, no CD8+ only segment. Patient 7: CD8+ only about 4, CD4+ only about 1 (4 to 5), red about 1 (5 to 6), total about 6. Highlighted points: white asterisks mark a hotspot mutation on patient 3 (light-blue segment) and patient 4 (red segment); footnote '* Hotspot mutation' below the axis. Chart is a flat raster image with no gridlines, no borders and a thin black outline on each bar segment. Right side has a bulleted list with red dot bullets.

Slide 14

Phase 2 translational data, poster presentation, ASCO 2026

The CD8+ and CD4+ neoantigen T cells are polyfunctional and cytotoxic

Polyfunctional

markers

Cytotoxic

markers

IFNγ

TNFα

Granzyme B

CD107a

CD8+ Neoantigen 14

CD4+ Neoantigen 27

19.8%

30.9%

0.72%

2.5%

8.3%

4.7%

75.0%

18.6%

DMSO

Peptides

Intracellular cytokine staining (ICS) of neoantigen reactive T cells from patient #3

14

© 2026 Moderna, Inc. All rights reserved.

Visuals: Figure: a two-column by two-row arrangement of four flow cytometry density/dot plots, reproduced as a raster image (1097 by 943 pixels, placed at x 28.0%, y 22.3%, w 39.2%, h 59.9%). Left column, titled Polyfunctional markers, has axes IFNγ (vertical) against TNFα (horizontal), with dense red dot clouds (Peptides) and blue dots (DMSO) and quadrant gates. Top-left panel quadrant values: 19.8% (upper left), 30.9% (upper right), 0.72% (lower right). Bottom-left panel quadrant values: 2.5% (upper left), 8.3% (upper right), 4.7% (lower right). Right column, titled Cytotoxic markers, has axes Granzyme B (vertical) against CD107a (horizontal), with colour density (blue, green, yellow, red contours) and a rectangular gate. Top-right panel labelled CD8+ Neoantigen 14 with gate value 75.0%; bottom-right panel labelled CD4+ Neoantigen 27 with gate value 18.6%. Row labels are vertical tabs: blue box #4A8BD0 with white text CD8+ Neoantigen 14 at x 86.6%, y 22.3% (w 3.4%, h 16.8%?); green box #109348 with white text CD4+ Neoantigen 27 below it. Legend at lower right of figure: blue square labelled DMSO and red square labelled Peptides. Plots have black frames and no gridlines; no logos or icons. Pink pixel-block decoration at bottom right (image 8 by 2 pixels scaled up at x 86.6%, y 92.2%, w 12.2%, h 4.9%) in light pink tints.

Slide 15

Phase 2 translational data, poster presentation, ASCO 2026 / The neoantigen-specific T cell clones detected after intismeran / Neoantigen 14; CD8+ / Neoantigen 27; CD4+ & CD8+ / Neoantigen 28; CD4+ & CD8+ / log10(count +1) / Screening / Post-pembrolizumab / Post-intismeran / Last intismeran dose / Follow up / Screening / Post-pembrolizumab / Post-intismeran / Last intismeran dose / Follow up / Screening / Post-pembrolizumab / Post-intismeran / Last intismeran dose / Follow up / Multiple T cell clones recognize same neoantigens / Method: AIM-based enrichment of CD4+ and CD8+ T cells ex vivo or after in vitro expansion; a >=5-cell / threshold per clonotype(n=57 for neoantigen 14, n=38 for neoantigen 27, n=28 for neoantigen 28) / 15 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Three line charts side by side, each titled in bold black Arial: left 'Neoantigen 14; CD8+', middle 'Neoantigen 27; CD4+ & CD8+', right 'Neoantigen 28; CD4+ & CD8+'. Each chart is a line chart with categorical x-axis labelled Screening, Post-pembrolizumab, Post-intismeran, Last intismeran dose, Follow up (labels rotated about 45 degrees, no axis title) and a y-axis titled log10(count +1) on the left chart only, with tick labels 0.0, 0.5, 1.0, 1.5, 2.0 on the left chart (about 0 to 2.3 range) and same scale on the other two with no tick labels. A dashed black vertical line marks Last intismeran dose in each chart. Values are estimates (no values printed): Left chart: light blue line about 0 to 1.55 at Post-intismeran rising to about 2.3 at Follow up; dark teal line about 0 to 1.58 then about 2.0 at Follow up; blue line about 0 to 1.2 then about 1.9 at Follow up; cyan line about 0 to 0.6 then about 1.8 at Follow up. Middle chart: dark red line about 0 to 0.9 then about 0.95 at Follow up; dark red line about 0 to 0.6 flat to Follow up about 0.6; red line about 0 to 0.6 then about 0.7 at Follow up; brownish orange line about 0 to 0.48 then about 0.3 at Follow up; red line about 0 to 0.48 then about 0 at Follow up; orange line about 0 to 0 then about 0.85 at Follow up. Right chart: olive line about 0 to 0.6 then about 1.0 at Follow up; dark gold line about 0 to 0.3 then about 0 at Follow up; yellow line about 0 to 0 then about 0.6 at Follow up. No legend; colours identify clones. Series are not highlighted. Below the charts a pink mosaic of about 8 by 2 square tiles in pale pink shades bottom-right.

Slide 16

Phase 3 INTerpath-001 adjuvant melanoma results shared at

ESMO 2026

October 22, 2026 2:59 PM

Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001

Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026

Presidential Symposium

Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001)

compared to KEYTRUDA alone for patients with completely resected stage IIB-IV melanoma

Benefit was greater after six months, following the intismeran immunization regimen, as intismeran plus KEYTRUDA reduced the risk of

recurrence or death by 58% (piecewise HR=0.42 [95% CI, 0.30–0.58]) compared to KEYTRUDA alone in a pre-specified sensitivity analysis

16

© 2026 Moderna, Inc. All rights reserved.

Visuals: One photograph-style screenshot (illustration of a web article) placed inside a white card. Subject: a press-release web article. Composition: the screenshot sits centred within the card, boxed with a navy date banner at the top of the article block, a bold dark grey headline in three lines, and two grey body paragraphs below. Lighting: flat, even, as a screen capture. Dominant colours: white, navy #1B3F66 for the date banner, near-black #222222 for the headline, mid grey #444444 for body text. Not cropped; the screenshot is boxed inside the card with white margin on all sides. The bottom edge of the card is a torn or ragged paper edge with a soft grey drop shadow, while the top corners of the card are rounded with a light shadow. No overlay or tint. A small decorative mosaic of pale pink squares (8 by 2 pixel grid, tiles in #F4C2CE and #EBC9D0 tones) sits in the bottom-right corner, not overlapping text.

Slide 17

Georgina Long / AO BSc PhD MBBS FRACP FAHMS / AAHMS FAA FASCO / Medical Director of Melanoma Institute / Australia (MIA), and Chair of Melanoma / Medical Oncology and Translational Research / at MIA and Royal North Shore Hospital, / The University of Sydney / 17 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Circular portrait photograph of a smiling woman with light-brown hair pulled back, gold hoop earrings, a gold necklace and a gold pin on her turquoise-blue blazer, looking toward the viewer; head and shoulders, centred in frame, cropped to a circle. Background is a blurred warm gold and grey interior with soft light. Lighting is soft and even, daylight. Dominant colours are turquoise blue, warm gold and grey. Around the photo is a broken circular ring: the upper-right arc is red (about #E31837) and the lower arc is bright blue (about #00A3E0), while the left arc is pale light blue (about #A8DDF2) with a fine textured look; gaps separate the arcs, and the ring sits just outside the photo with a white gap between. Bottom-right of slide is a block of small pink squares in a grid (about 8 by 2 tiles) in pale pink tones from #F4C2CD to #EBD3D8, decorative.

Slide 18

REPRISE: ESMO 2026 PRESENTATION / INTerpath-001: Phase 3 Study of the mRNA-Based / Individualized Neoantigen Therapy (INT) Intismeran / Autogene plus Pembrolizumab vs Pembrolizumab / Alone for Adjuvant Treatment of Resected Stage IIB- / IV Melanoma / Georgina Long, / AO BSc PhD MBBS FRACP FAHMS AAHMS FAA FASCO / Medical Director of Melanoma Institute Australia / Georgina V. Long; Muhammad A. Khattak; Helen J. Gogas; Dirk Schadendorf; Ana Arance; Matteo S. Carlino; Piotr Rutkowski; / Gareth Rivalland; Antoni Ribas; Janice M. Mehnert; Patrick A. Ott; Reinhard Dummer; Paola Queirolo; Christoffer Gebhardt; / Laureen S. Ojalvo; Jinchun Zhang; Dmitri O. Grebennik; Mizuho Fukunaga-Kalabis; Paolo A. Ascierto; Michele Del Vecchio on / behalf of the INTerpath-001 Investigators / 1Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, NSW, Australia; 2One Clinical Research, Hollywood Private Hospital and Edith / Cowan University, Perth, WA, Australia; 3Saint John of God Subiaco Hospital, Subiaco, WA, Australia; 4Washington University School of Medicine, St. Louis, MO, USA; 5Earle A. Chiles / Research Institute, Providence Cancer Institute, Portland, OR, USA; 6California Pacific Medical Center Research Institute, San Francisco, CA, USA; 7Sarah Cannon Research Institute, / Nashville, TN, USA; 8Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; 9Massachusetts General Hospital, / Harvard Medical School, Boston, MA, USA; 10The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, Los Angeles, CA, USA; 11Smilow Cancer Center at Yale New Haven Hospital, / New Haven, CT, USA; 12Texas Oncology PA, Dallas, TX, USA; 13Hackensack University Medical Center, Hackensack, NJ, USA; 14University of Colorado Cancer Center, Aurora, / CO, USA; 15Princess Alexandra Hospital, Brisbane, QLD, Australia; 16Merck & Co., Inc., Rahway, NJ, USA; 17Moderna, Inc., Cambridge, MA, USA; 18Laura and Isaac / Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA / © 2026 Moderna, Inc. All rights reserved.

Visuals: Decorative pixel mosaic in the bottom-right corner, 8 columns by 2 rows of square tiles, boxed at x 86.6%, y 92.2%, width 12.2%, height 4.9%. Tiles range from pale pink (#F6D3DD) to deeper rose (#E4B3C1), with the central columns darker and the outer columns lighter, and no overlay or cropping. No photographs, charts, tables, logos or icons.

Slide 19

MADRID 2026

ESMO congress

INTerpath-001: Phase 3 Study of the mRNA-Based Individualized Neoantigen Therapy (INT) Intismeran Autogene plus Pembrolizumab vs Pembrolizumab Alone for Adjuvant Treatment of Resected Stage IIB-IV Melanoma

Georgina V. Long; Muhammad A. Khattak; Helen J. Gogas; Dirk Schadendorf; Ana Arance; Matteo S. Carlino; Piotr Rutkowski; Gareth Rivalland; Antoni Ribas; Janice M. Mehnert; Patrick A. Ott; Reinhard Dummer; Paola Queirolo; Christoffer Gebhardt; Laureen S. Ojalvo; Jinchun Zhang; Dmitri O. Grebennik; Mizuho Fukunaga-Kalabis; Paolo A. Ascierto; Michele Del Vecchio on behalf of the INTerpath-001 Investigators

19

© 2026 Moderna, Inc. All rights reserved.

Visuals: Illustration: a faded silhouette of a historic European city skyline (Prague-style) across the bottom-right of the white card, spanning roughly 56% to 89% of the slide width and 56% to 89% of the height. It shows a stone bridge with rounded arches at the bottom left of the skyline, a pale blue domed church with a small spire, a tall orange-brown tower with arched openings, a dark navy clock tower, and olive-green and cream angular shapes resembling a stylised gate or spire, with a dark navy spire at the far right edge. Colours are muted ochre #E0A030, slate blue #6A86A8, olive #8A9A3A, orange #E08A4A and cream #F2E6C0, rendered semi-transparent over white. The illustration runs to the bottom edge of the card and is cropped at the card edge on the right. A small pink pixelated mosaic block (8 by 2 cells, light pink #F0C4D0 to pale #F8E4EA) sits at the bottom-right corner outside the card. A small ESMO logo sits in the bottom-right corner of the card on a white rounded tab.

Slide 20

Declaration of Interests

Georgina V. Long

• Consultant advisor: BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Byondis B.V., Evaxion, Fortiva Biologics, GI Innovation, Immunocore, Innovent Biologics USA, Iovance Biotherapeutics, Jazz Pharmaceuticals, MSD, Replimune, Regeneron, Scancell, Strand Therapeutics

• Principal investigator: more than 60 clinical trials

All Authors

• Funding to institution to support conduct of INTerapth-001: Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD) and Moderna, Inc., Cambridge, MA, USA

• Medical writing and editorial support for this presentation: Provided by Melanie Leiby of MSD

Presented by: Georgina V. Long, Melanoma Institute Australia

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.

20

© 2026 Moderna, Inc. All rights reserved.

Visuals: A small ESMO Congress logo at bottom right of the panel: a blue 'MADRID 2026' tag, a green-and-red 'ESMO' wordmark with the letter O in dark blue, and 'congress' in blue superscript. A pink mosaic of translucent square tiles in the bottom-right corner of the slide, about 12% wide, in light pinks. No photographs, charts or diagrams.

Slide 21

Despite RFS and DMFS benefit for adjuvant PD-1 inhibition in / phase 3 melanoma trials, many patients have recurrence1-10 / EORTC-1325/KEYNOTE-0541 / Pembrolizumab vs placebo, stage III / KEYNOTE-7162 / Pembrolizumab vs placebo, stage IIB/IIC / RFS, % / Years / HR 0.63 (95% CI, 0.53-0.74) / ~ 44% recur / or die by / 5 years / RFS, % / Years / HR 0.62 (95% CI, 0.50-0.76) / ~ 33% recur / or die by / 5 years / 1Eggermont AMM et al. Eur J Cancer 2024;211:114327. 2Luke JJ et al. Ann Oncol 2025;36:abstr 1611P. 3Eggermont AMM et al. N Engl J Med 2018;378:1789-1801. 4Eggermont AMM et al. Lancet Oncol 2021;22:643-54. 5Luke JJ et al. Lancet 2022;399:1718-29. 6Long GV et al. Lancet Oncol 2022;23:1378-88. 7Weber J et al. N Engl J Med 2027;377:1824-35. 8Ascierto PA et al. Lancet Oncol 2020;21:1465-77. 9Kirkwood JM et al. Nat Med 2023;29:2835-43. 10Ascierto PA et al. N Engl J Med 2026;394:333-42. / Presented by: Georgina V. Long, Melanoma Institute Australia / Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. / 21 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Two Kaplan-Meier survival line charts side by side. Left chart: EORTC-1325/KEYNOTE-054, pembrolizumab vs placebo, stage III. Y axis titled RFS, % from 0 to 100 in steps of 10; X axis titled Years from 0 to 9 in steps of 1. Two step curves: a blue upper curve starting at 100 and falling to about 50 at 8 years, and a red lower curve starting at 100 and falling to about 33 at 8 years. Both curves have small tick marks for censored patients. A red double-headed vertical arrow sits at about 5 years spanning the gap between the curves, labelled ~ 44% recur or die by 5 years; a black dashed vertical line marks 5 years. Blue curve at 5 years is about 56 and red about 39. Text HR 0.63 (95% CI, 0.53-0.74) sits in the lower-left of the plot in navy. Right chart: KEYNOTE-716, pembrolizumab vs placebo, stage IIB/IIC. Y axis RFS, % from 0 to 100 in steps of 10; X axis Years from 0 to 6 in steps of 1. Blue upper curve falls from 100 to about 67 at 6 years; red lower curve falls to about 52 at 6 years. Red double-headed arrow at about 5 years labelled ~ 33% recur or die by 5 years, with a black dashed line at 5 years; at 5 years blue is about 68 and red about 53. Text HR 0.62 (95% CI, 0.50-0.76) in the lower-left of the plot in navy. Both charts have black axes with no gridlines and no legend; the colour coding of curves is not labelled on the slide. Small ESMO Congress Madrid 2026 logo at bottom right of the panel: a blue MADRID 2026 tag next to green and navy ESMO letters with the word congress in blue superscript. A pixelated pink-to-light-pink mosaic block sits at the bottom right of the page outside the panel.

Slide 22

Dual checkpoint blockade in the adjuvant setting has failed to improve efficacy while increasing toxicity in phase 3 trials

CheckMate 915¹

RFS: HR 0.92 P = 0.269

Grade 3-4 TRAEs: 32.6% vs 12.8%

RELATIVITY-098²

RFS: HR 1.01 P = 0.928

Grade 3-4 TRAEs: 19.0% vs 8.4%

KEYVIBE-010³

RFS: HR 1.25 (95% CI 0.9-1.8)

Grade 3-5 TRAEs: 16% vs 7%

RFS, %

100 90 80 70 60 50 40 30 20 10

0 3 6 9 12 15 18 21 24 27 30 33 36 39

Months

Nivo + Ipi (1 mg/kg Q6W)

Nivo

100 80 60 40 20 0

0 3 6 9 12 15 18 21 24 27 30 33 36

Months

Nivo + Relatlimab

Nivo

100 80 60 40 20 0

0 3 6 9 12

Months

Vibo/Pembro Coformulation

Pembro

1 Weber JS et al. J Clin Oncol 2023;41:517-27. 2 Long GV et al. Nat Med 2025;31:4301-9. 3 Dummer R et al. Lancet Oncol 2026;27:327-39.

Presented by: Georgina V. Long, Melanoma Institute Australia

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.

22

© 2026 Moderna, Inc. All rights reserved.

Visuals: Three Kaplan-Meier survival-style line charts, side by side, each with the same structure. Y axis: RFS, % from 0 to 100 with ticks every 10 (lower limit 0 only on the two right charts). X axis: Months. Chart 1 (CheckMate 915): x ticks 0 to 39 every 3, y 10 to 100 shown; series 'Nivo + Ipi (1 mg/kg Q6W)' in red and 'Nivo' in blue, both declining from 100 to about 57 at about 36 months, with the curves nearly overlapping, red slightly above blue after about 12 months; no values printed beyond the axes. Chart 2 (RELATIVITY-098): x ticks 0 to 36 every 3, y 0 to 100 every 20; series 'Nivo + Relatlimab' in cyan and 'Nivo' in lime green, both falling from 100 to about 60 by 24 months and about 55 at 36 months; the green Nivo curve drops to about 40 at about 33 months while cyan stays about 55; no values printed. Chart 3 (KEYVIBE-010): x ticks 0, 3, 6, 9, 12 months, y 0 to 100 every 20; series 'Vibo/Pembro Coformulation' in blue and 'Pembro' in red; both start at 100, drop to about 80 by 6 months, the red curve stays about 85 then about 81 from about 9 months to 11.5 months, the blue curve falls to about 68 by 11 months; tick marks (censoring) visible on both lines; no values printed. Legends are placed as coloured text labels inside each plot's lower-left area, not as boxed legends. No highlighted points.

Slide 23

Science enables individualized therapeutic cancer vaccines / Neoantigen discovery / • Tumor-specific mutations / • Potential for enhanced immunogenicity / Neoantigen selection / • NGS identifies tumor mutations / • Computational prediction of HLA presentation and ranking / The mRNA platform / • Multiple antigens per mRNA / • Robust CD8+ and CD4+ T cell responses / • Rapid, individualized manufacturing / Cancer Cell / Patient A / Patient B / Patient C / Lipid nanoparticle (LNP) / mRNA / Intismeran autogene, a type of individualized neoantigen therapy (INT) / • Composed of an mRNA encoding up to 34 neoantigens encapsulated in LNP / • Specific to each patient's tumor mutanome and HLA type / HLA, human leukocyte antigen; mRNA, messenger RNA; NGS, next-generation sequencing. / Ascierto PA, Melero I. J Immunother Cancer 2025;13:e013766. Zaidi N et al. Nat Rev Cancer 2025;25:517–33. Haanen JB et al. Nat Med 2026;32:828-40. Weber JS et al. Lancet 2024;403:632–44. Ojalvo LS et al. JCO Oncol Adv 2026;3:e2500206. / Presented by: Georgina V. Long, Melanoma Institute Australia / Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. / 23 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Three cell illustrations in a row above the bracket: Patient A has a blue cell with a green, orange and grey receptor-like marker on top; Patient B has a grey-blue cell with red, pink and orange markers; Patient C has a light blue cell with purple, blue and magenta markers; the cell label 'Cancer Cell' sits above them. A flat navy computer monitor icon in the middle shows a grid of blue and green horizontal dashes representing sequence reads. A lipid nanoparticle illustration on the right is a pale circle with a green dotted rim and a black wavy strand inside, with two thin navy leader arrows pointing to 'Lipid nanoparticle (LNP)' and 'mRNA'. A navy horizontal bracket spans the width under the cells and monitor with a centred navy down arrow pointing to the conclusion text. Small ESMO Congress logo with a MADRID 2026 badge at bottom right of the slide panel. A pink pixel mosaic in the page bottom-right corner.

Slide 24

Standardized intismeran workflow / 2 / Neoantigen / identification / 3 / mRNA / design / 4 / Manufacture / 5 / Administer / 1 / Tissue and blood / samples / ~6-8 weeks / Presented by: Georgina V. Long, Melanoma Institute Australia / Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. / MADRID 2026 ESMO congress / 24 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Diagram: a five-step circular workflow. Step 1 'Tissue and blood samples' (blue rounded box, white label, numbered white circle with navy '1') sits at lower left, linked by a blue curved arrow running up-left to step 2. Step 2 'Neoantigen identification' (blue box, numbered circle '2') sits upper left, next to a red-outline monitor icon with coloured horizontal lines (red, blue, orange dashes) on a red stand. A blue arc with arrowhead runs from the monitor rightward across the top to a red-and-orange-and-blue DNA double-helix icon beside step 3 'mRNA design' (blue box, numbered circle '3', upper right). A blue arc runs down from step 3 to a red vial icon beside step 4 'Manufacture' (blue box, numbered circle '4', right). A blue arc runs down from step 4 to a red syringe icon angled down-left beside step 5 'Administer' (blue box, numbered circle '5', lower right). A blue arc with arrowhead runs from the syringe down-left back to step 1, closing the loop. Centre: a red-outline human figure (circle head, shoulders and torso, two short vertical red lines for arms or body detail) with the caption '~6-8 weeks' in bold navy below its feet. Left of step 1: a red gear-like cell or virus icon with a red circle at its centre and red nodules around its edge. Arrows are blue (#1F6FD0 approx.) strokes about 3 pt with open arrowheads. Icons are red #D32F2F outlines with orange and blue accents. The ESMO congress logo at bottom right shows a blue 'MADRID 2026' tag, a green 'ESMO' wordmark with red O, and blue 'congress' text. Pink mosaic tiles at bottom right corner outside the panel, light pink (#F2C4CC approx.) fading to pale tones.

Slide 25

Intismeran mechanism of action

• Intismeran is designed to strengthen existing and create new T cell responses1-3

• Pembrolizumab blocks PD-1 to enhance T-cell activity, complementing intismeran's MOA

1 Administer INT

2 mRNA uptake / into cells

3 mRNA translated into / protein and processed

APC / (eg, dendritic cell)

Endosome

Endoplasmic / reticulum

CD8 T cell / (cytotoxic activity)

INT mRNA

Polypeptide

Proteasome

Tumor-specific / neoantigens

MHC I

4 Neoantigen / presentation

Endo- / lysosomes

MHC II

CD4 T cell / (memory)

Dying / tumor cell

CD4+ / T cell

CD8+ / T cell

Cytokine / release

7 Tumor cell / killing

8 Epitopes / releaseda

T cells

5 T cell activation and / clonal expansion

6 Migration to tumor / microenvironment

aHypothetical mechanism of action.

1Weber JS et al. Lancet 2024;403:632–44. 2Ojalvo LS et al. JCO Oncol Adv 2026;3:e2500206. 3Gainor JF, et al. Cancer Discov. 2024;14(11):2209-2223

Presented by: Georgina V. Long, Melanoma Institute Australia

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.

25

© 2026 Moderna, Inc. All rights reserved.

Visuals: One diagram: a circular cycle of eight numbered rounded rectangles (dark blue #1F5597 with white text) linked by large pale grey curved arrows, showing steps 1 Administer INT, 2 mRNA uptake into cells, 3 mRNA translated into protein and processed, 4 Neoantigen presentation, 5 T cell activation and clonal expansion, 6 Migration to tumor microenvironment, 7 Tumor cell killing, 8 Epitopes released. Illustrations: a syringe injecting into an upper arm (grey and skin tones, left of centre); a virus-like lipid nanoparticle with a red-circled inset of an mRNA strand; a brown dendritic cell (APC) with orange tips; a large beige antigen-presenting cell with an inset showing endosome, INT mRNA, endoplasmic reticulum, polypeptide, proteasome, tumor-specific neoantigens, endo-lysosomes, MHC I and MHC II, next to a green CD8 T cell and a blue CD4 T cell; a pink dying tumor cell with a grey crosshair target; green and blue CD4+ and CD8+ T cells releasing cytokines; a pink tumour mass with green and blue immune cells; a cluster of green and blue T cells. Light-blue translucent wedge fills the space between the APC and the dendritic cell. Flat vector style, no photographs.

Slide 26

KEYNOTE-942: Phase 2b trial of pembrolizumab ± intismeran: / Proof of concept in stage IIIB–IV resected melanoma / RFS2 / DMFS2 / Median (95% CI), months / Events, % (n/N) / Hazard ratio (95% CI) / Intismeran plus pembrolizumab / NE / 26.2 (28/107) / 0.510 (0.294–0.887) / Pembrolizumab / 44.65 (16.59–NE) / 46.0 (23/50) / 80.4% / 78.3% / 73.8% / 72.4% / 62.2% / 60.0% / 55.6% / 49.1% / Recurrence-Free Survival, % / Time From First Dose of Pembrolizumab, Months / Median (95% CI), months / Events, % (n/N) / Hazard ratio (95% CI) / Intismeran plus pembrolizumab / NE / 14.0 (15/107) / 0.411 (0.200–0.843) / Pembrolizumab / NE (27.07–NE) / 30.0 (15/50) / 92.0% / 90.8% / 85.6% / 83.9% / 73.0% / 70.6% / 65.4% / 65.4% / Distant Metastasis-Free Survival, % / Time From First Dose of Pembrolizumab, Months / • Intismeran + pembrolizumab significantly improved RFS and DMFS and had a tolerable safety profile1 / – Clinical benefit durable at 5 years2 / • Intismeran-induced immune responses are associated with clinical outcomes2 / – Greater sustained expansion of novel T-cell clonotypes was associated with lack of recurrence2,3 / • Novel T-cell clonotypes were mapped to intismeran-encoded neoantigens and functionally validated3 / 1Weber JS et al. Lancet 2024;403:632–44. 2Khattak A et al. J Clin Oncol 2026;44:2482–9. 3Sullivan RJ et al. J Clin Oncol 2026;44:abstr 9564. / Presented by: Georgina V. Long, Melanoma Institute Australia / Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. / MADRID 2026 ESMO congress / 26 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Two Kaplan-Meier survival line charts side by side, each with a dark navy bold title (RFS2 left, DMFS2 right) and a dark navy data table beneath the plot. Left chart: RFS2, y-axis Recurrence-Free Survival, % from 0 to 100 in steps of 10; x-axis Time From First Dose of Pembrolizumab, Months from 0 to 66 in steps of 6; dashed vertical reference lines at 18, 24, 36 and 48 months. Series red (intismeran plus pembrolizumab): about 100 at 0, 80.4% labelled near 18 months, 78.3% labelled at 24 months, 73.8% labelled at 36 months, 72.4% labelled at 48 months, about 69 at 60 months. Series light blue (pembrolizumab): 62.2% labelled near 18 months, 60.0% labelled at 24 months, 55.6% labelled at 36 months, 49.1% labelled at 48 months, about 49 at 60 months. Small tick marks on both curves indicate censored patients. Right chart: DMFS2, y-axis Distant Metastasis-Free Survival, % from 0 to 100 in steps of 10; x-axis Time From First Dose of Pembrolizumab, Months from 0 to 66 in steps of 6; dashed vertical lines at 18, 24, 36 and 48 months. Red curve: 92.0% at 18 months, 90.8% at 24 months, 85.6% at 36 months, 83.9% at 48 months, about 80 at 60 months. Light blue curve: 73.0% at 18 months, 70.6% at 24 months, 65.4% at 36 months, 65.4% at 48 months, about 66 at 60 months. Each chart has a dark navy table below the plot with header row (navy fill, white text): Median (95% CI), months / Events, % (n/N) / Hazard ratio (95% CI). Row 1 red text: Intismeran plus pembrolizumab, NE, 26.2 (28/107), 0.510 (0.294–0.887) on the left and NE, 14.0 (15/107), 0.411 (0.200–0.843) on the right. Row 2 blue text: Pembrolizumab, 44.65 (16.59–NE), 46.0 (23/50) on the left and NE (27.07–NE), 30.0 (15/50) on the right. No legend is printed; the series are identified by colour in the table rows. No highlighted points beyond the printed labels. Below the bullets and footnotes is the ESMO Congress logo at bottom right: a small blue rounded tag reading MADRID 2026, followed by ESMO in bold letters in green, blue and red and the word congress in small blue italics at top right. Bottom right corner also has a pale pink mosaic of small squares (pink to white gradient) placed in the template footer.

Slide 27

INTerpath-001: Randomized, Double-Blind, Phase 3 Trial

Key Eligibility Criteria

Age ≥18 years

Resected cutaneous melanoma

AJCC 8th ed. Stage IIB/IIC (clinical IIB/IIC permitted), III, or IV

FFPE tumor sample suitable for NGS and intismeran generation

No prior systemic therapy

ECOG PS 0 or 1

Stratification factors

Risk-based stage (IIB/IIC/IIIA/IIIB vs IIIC/IIID/IV)

Age (<65 years vs ≥65 years)

R 2:1

Intismeran

1 mg IM Q3W for 9 doses

+

Pembrolizumab

400 mg IV Q6W for 9 cycles

Placebo a

IM Q3W for 9 doses

+

Pembrolizumab

400 mg IV Q6W for 9 cycles

Pembrolizumab

Started at randomization, ≤13 weeks after resection

Intismeran

Started upon availability to site

Earliest: Cycle 1, day 22

Latest: Cycle 4, day 1

Primary end point: RFS per investigator

Secondary end points: DMFS per investigator, OS, patient-reported outcomes, safety

a Normal saline or dextrose. Placebo was started at random to maintain the blind.

ClinicalTrials.gov identifier: NCT05933577.

Presented by: Georgina V. Long, Melanoma Institute Australia

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.

27

© 2026 Moderna, Inc. All rights reserved.

Visuals: Flow diagram: a dark grey rectangle labelled Key Eligibility Criteria with six bullets connects by a horizontal navy line to a dark grey circle labelled R 2:1; from the circle a vertical navy line with two right-angled connectors ends in arrowheads at the top teal box (Intismeran, 1 mg IM Q3W for 9 doses + Pembrolizumab 400 mg IV Q6W for 9 cycles) and the lower blue box (Placebo a, IM Q3W for 9 doses + Pembrolizumab 400 mg IV Q6W for 9 cycles). Two stacked rectangular text boxes sit beside them, and a small MADRID 2026 ESMO congress logo sits bottom right. The only raster elements are the slide picture and a pink mosaic of small squares in the bottom-right page corner.

Slide 28

Key Statistical Considerations / Statistical methods / Hierarchical testing^a: order of RFS → DMFS → OS / Between-group treatment differences: stratified log-rank test^b / Magnitude of treatment differences / –Primary method: HR (95% CI) based on stratified Cox regression model^b in ITT population / –Sensitivity analysis 1: unstratified piecewise HRs (95% CIs) in ITT population / –Sensitivity analysis 2: HR (95% CI) based on stratified Cox regression model^b in mITT population^c / Interim analysis 1 (IA1) / Timing: after ~240 RFS events and ≥18 months after last patient randomized / Data cutoff date: June 30, 2026 / –Median follow-up^d: 24.6 months (range, 18.2–34.5) / ^aThe overall type I error was strongly controlled at one-sided 0.025 across RFS, DMFS, and OS. All alpha was initially allocated to RFS; alpha was transferred to DMFS and OS only if the preceding end point was significant. ^bRandomization stratification factors applied to all stratified analyses. ^cModified ITT (mITT) population included all randomized patients who received intismeran or placebo as planned. ^dDefined as time from randomization to the data cutoff date. / Presented by: Georgina V. Long, Melanoma Institute Australia / Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. / 28 / © 2026 Moderna, Inc. All rights reserved.

Visuals: None apart from the ESMO Congress 2026 Madrid logo (blue 'MADRID 2026' tag, green-and-navy 'ESMO' wordmark, and 'congress' in blue lowercase at bottom right of the slide panel) and a decorative pink-to-light-pink mosaic of small squares in the bottom right corner of the page (outside the slide panel). No charts, tables or photographs.

Slides 29 to 52 continue in the full text file.

Download this deck

The hosted PDF of every library deck is free for readers of the SlideDeck Co newsletter. Join with your email and the viewer and download appear here.

Preparing a results presentation or business update of your own? The SlideDeck Co Standard Deck is a slide library for business reviews, updates and plans.

More Reporting decks

Deck reviews in your inbox.

See what works in real company decks, what we’d change, and get the latest SDC releases.

Expanded slide preview